NGM Biopharmaceuticals Inc. launched the 11th biopharmaceutical initial public offering in the US this year and was the second non-alcoholic steatohepatitis (NASH) drug developer to initiate an IPO in 2019, but the company's stock didn't fare as well as NASH company Genfit SA's shares a week earlier.
South San Francisco-based NGM Bio priced 6.67m shares at $16 each on April 3 to net $95.7m before the sale...






